Inventor
CLAIBORNE CHRISTOPHER F
US35 patents
⚠️ This page may combine multiple inventors who share the name “CLAIBORNE CHRISTOPHER F”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
MILLENNIUM PHARM INC
15 patentsUS7572784B2Aug 11, 2009
Compounds and methods for inhibiting mitotic progression
MILLENNIUM PHARM INC38 citations95
US9765078B2Sep 19, 2017
Compounds and methods for inhibiting mitotic progression
MILLENNIUM PHARM INC11 citations92
US9765076B2Sep 19, 2017
Aurora kinase inhibitors for inhibiting mitotic progression
MILLENNIUM PHARM INC13 citations92
US9102678B2Aug 11, 2015
Compounds and methods for inhibiting mitotic progression
MILLENNIUM PHARM INC13 citations92
US8008307B2Aug 30, 2011
Heteroaryl compounds useful as inhibitors of E1 activating enzymes
MILLENNIUM PHARM INC25 citations91
US10836766B2Nov 17, 2020
Aurora kinase inhibitors for inhibiting mitotic progression
MILLENNIUM PHARM INC5 citations84
US7718648B2May 18, 2010
Pyridobenzazepine compounds and methods for inhibiting mitotic progression
MILLENNIUM PHARM INC15 citations84
US9150525B2Oct 6, 2015
Heteroaryl compounds useful as inhibitors of E1 activating enzymes
MILLENNIUM PHARM INC10 citations83
US7935694B2May 3, 2011
Lactam compounds useful as protein kinase inhibitors
MILLENNIUM PHARM INC8 citations82
US10414770B2Sep 17, 2019
Compounds and methods for inhibiting mitotic progression
MILLENNIUM PHARM INC1 citations72
US9458108B2Oct 4, 2016
Heteroaryl compounds useful as inhibitors of E1 activating enzymes
MILLENNIUM PHARM INC3 citations72
US7459448B2Dec 2, 2008
Lactam compounds useful as protein kinase inhibitors
MILLENNIUM PHARM INC8 citations71
US11958855B2Apr 16, 2024
Aurora kinase inhibitors for inhibiting mitotic progression
MILLENNIUM PHARM INC0 citations62
US11014928B2May 25, 2021
Compounds and methods for inhibiting mitotic progression
MILLENNIUM PHARM INC0 citations62
US9718788B2Aug 1, 2017
Heteroaryl compounds useful as inhibitors of E1 activating enzymes
MILLENNIUM PHARM INC0 citations51
MERCK & CO INC
14 patentsUS6083949AJul 4, 2000
Substituted imidazoles having anti-cancer and cytokine inhibitory activity
MERCK & CO INC28 citations93
US6376530B1Apr 23, 2002
Cyclic amidines useful as NMDA NR2B antagonists
MERCK & CO INC22 citations92
US6316474B1Nov 13, 2001
2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
MERCK & CO INC43 citations92
US6303637B1Oct 16, 2001
Heterocyclic potassium channel inhibitors
MERCK & CO INC39 citations92
US6207687B1Mar 27, 2001
Substituted imidazoles having cytokine inhibitory activity
MERCK & CO INC21 citations92
US6194458B1Feb 27, 2001
Benzamide potassium channel inhibitors
MERCK & CO INC43 citations92
US6632836B1Oct 14, 2003
Carbocyclic potassium channel inhibitors
MERCK & CO INC45 citations90
US6319944B1Nov 20, 2001
Aryl amidines, compositions containing such compounds and methods of use
MERCK & CO INC21 citations90
US7592360B2Sep 22, 2009
3-fluoro-piperidines as NMDA/NR2B antagonists
MERCK & CO INC18 citations84
US7259157B2Aug 21, 2007
N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists
MERCK & CO INC12 citations83
US7053089B2May 30, 2006
N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists
MERCK & CO INC13 citations82
US7217716B2May 15, 2007
N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists
MERCK & CO INC8 citations72
US6767908B2Jul 27, 2004
Substituted imidazoles having cytokine inhibitory activity
MERCK & CO INC4 citations63
US6291457B1Sep 18, 2001
Compounds having cytokine inhibitory activity
MERCK & CO INC1 citations51